- Update on global clinical progress of core pipeline assets HER2-ADC and ROR1-ADC
- Unveiling of next-generation ADC pipeline and strategic expansion into immuno-oncology sector
[by Ji, Yong Jun] LigaChem Biosciences (hereinafter referred to as LCB) announced on June 26 that it will host 'LigaChemBio Global 실시간-바카라사이트amp;D DAY 2025' in Yeouido, Seoul, on July 1.
The event will serve as a platform for LCB to present its current 실시간-바카라사이트amp;D status and mid- to long-term strategic plans to key stakeholders, including investors, analysts, and media representatives. It will also highlight the company's globally competitive antibody-drug conjugate (ADC) technology and its broader business vision. To engage both Korean and international investors and ADC experts, the event will be live-streamed on YouTube in both Korean and English.
The first part of the event will feature an analysis of the scalability of ADC technology, along with a presentation detailing how LCB's platform technology is differentiated in terms of clinical strategy. In addition, the session will include updates on the global clinical 실시간-바카라사이트 status of core pipelines such as HER2-ADC and ROR1-ADC, real-world application cases, interim results of Phase 1 clinical trials, and future 실시간-바카라사이트 plans.
The second part of the event will center on next-generation ADC technologies and innovation in the field of immuno-oncology. This session will introduce a range of innovative candidates currently under development while also highlighting the distinctiveness of recently acquired targets and outlining the company’s strategic plans for expanding its technological platform into the immuno-oncology sector.
In the final session, LCB will outline its global 실시간-바카라사이트 strategy and long-term growth vision. This will include detailed plans for technology transfer aimed at expanding international partnerships, as well as a mid- to long-term 실시간-바카라사이트 roadmap and key growth drivers through 2030. Each presentation will be followed by an in-depth Q&A session, fostering direct discussion with attendees.
LCB is actively advancing the 실시간-바카라사이트 of next-generation ADCs through its proprietary ConjuALL platform technology, with multiple pipeline candidates having already progressed into clinical stages.
"Through Global R&D DAY, we aim to comprehensively showcase the distinct competitiveness of our ADC technology, our strategic expansion into the immuno-oncology field, and our approach to forming global partnerships. This event will serve to further concretize our vision of becoming a leading company in the development of next-generation anticancer treatments," an LCB official emphasized.